122 related articles for article (PubMed ID: 37942762)
21. Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma.
Nath K; Law SC; Sabdia MB; Gunawardana J; de Long LM; Sester D; Shanavas M; Tsang H; Tobin JWD; Halliday SJ; Hernandez A; Cross D; Bird RJ; Jain S; Keane C; Talaulikar D; Trotman J; Law P; Gandhi MK
Blood Adv; 2021 Jun; 5(12):2644-2649. PubMed ID: 34156439
[TBL] [Abstract][Full Text] [Related]
22. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
23. Volumetric parameters from [
Langen Stokmo H; Aly M; Bowitz Lothe IM; Borja AJ; Mehdizadeh Seraj S; Ghorpade R; Miao X; Hjortland GO; Malinen E; Sorbye H; Werner TJ; Alavi A; Revheim ME
J Neuroendocrinol; 2022 Jul; 34(7):e13170. PubMed ID: 35729738
[TBL] [Abstract][Full Text] [Related]
24. Metabolic tumor burden on baseline
Chen S; He K; Feng F; Wang S; Yin Y; Fu H; Wang H
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1830-1839. PubMed ID: 31187163
[TBL] [Abstract][Full Text] [Related]
25. The prognostic relationship of 18F-FDG PET/CT metabolic and volumetric parameters in metastatic ALK + NSCLC.
Agüloğlu N; Aksu A; Unat DS; Akyol M
Nucl Med Commun; 2022 Dec; 43(12):1217-1224. PubMed ID: 36345766
[TBL] [Abstract][Full Text] [Related]
26. Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer.
Jin P; Bai M; Liu J; Yu J; Meng X
Front Immunol; 2022; 13():1004351. PubMed ID: 36341372
[TBL] [Abstract][Full Text] [Related]
27. FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer.
Seban RD; Assie JB; Giroux-Leprieur E; Massiani MA; Soussan M; Bonardel G; Chouaid C; Playe M; Goldfarb L; Duchemann B; Girard N; Champion L
Ann Nucl Med; 2020 Dec; 34(12):968-974. PubMed ID: 33070295
[TBL] [Abstract][Full Text] [Related]
28. Metabolic tumour volume in Hodgkin lymphoma-A comparison between manual and AI-based analysis.
Sadik M; Barrington SF; Trägårdh E; Saboury B; Nielsen AL; Jakobsen AL; Gongora JLL; Urdaneta JL; Kumar R; Edenbrandt L
Clin Physiol Funct Imaging; 2024 May; 44(3):220-227. PubMed ID: 38011940
[TBL] [Abstract][Full Text] [Related]
29. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma.
Toledano MN; Desbordes P; Banjar A; Gardin I; Vera P; Ruminy P; Jardin F; Tilly H; Becker S
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):680-688. PubMed ID: 29344718
[TBL] [Abstract][Full Text] [Related]
30. Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial.
Schmitz C; Rekowski J; Müller SP; Hertenstein B; Franzius C; Ganser A; Bengel FM; Kroschinsky F; Kotzerke J; La Rosée P; Freesmeyer M; Hoeffkes HG; Hertel A; Behringer D; Mesters R; Weckesser M; Mahlmann S; Haberkorn U; Martens U; Prange-Krex G; Brenner W; Giagounidis A; Moeller R; Runde V; Sandmann M; Hautzel H; Wilop S; Krohn T; Dürk H; Heike M; Alashkar F; Brinkmann M; Trenn G; Wacker D; Kreisel-Büstgens C; Bernhard H; Heil G; Larisch R; Kurch L; Jöckel KH; Hoelzer D; Klapper W; Boellaard R; Dührsen U; Hüttmann A
Hematol Oncol; 2020 Aug; 38(3):244-256. PubMed ID: 32067259
[TBL] [Abstract][Full Text] [Related]
31. Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG.
Binkley MS; Brady JL; Hajj C; Chelius M; Chau K; Balogh A; Levis M; Filippi AR; Jones M; Ahmed S; MacManus M; Wirth A; Oguchi M; Vistisen AK; Andraos TY; Ng AK; Aleman BMP; Choi SH; Kirova YM; Hardy S; Reinartz G; Eich HT; Bratman SV; Constine LS; Suh CO; Dabaja B; El-Galaly TC; Hodgson DC; Ricardi U; Yahalom J; Mikhaeel NG; Hoppe RT
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):522-529. PubMed ID: 30858143
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis.
Guo B; Tan X; Ke Q; Cen H
PLoS One; 2019; 14(1):e0210224. PubMed ID: 30625203
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of pre-transplantation total metabolic tumor volume on
Sugio T; Baba S; Mori Y; Yoshimoto G; Kamesaki K; Takashima S; Urata S; Shima T; Miyawaki K; Kikushige Y; Kunisaki Y; Numata A; Takenaka K; Iawasaki H; Miyamoto T; Ishigami K; Akashi K; Kato K
Int J Hematol; 2022 Oct; 116(4):603-611. PubMed ID: 35701707
[TBL] [Abstract][Full Text] [Related]
34. Metabolic bulk volume from FDG PET as an independent predictor of progression-free survival in follicular lymphoma.
So H; Lee H; Hyun SH; Cho YS; Moon SH; Choi JY; Lee KH
Front Oncol; 2023; 13():1283582. PubMed ID: 38023238
[TBL] [Abstract][Full Text] [Related]
35. Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma.
Cottereau AS; Lanic H; Mareschal S; Meignan M; Vera P; Tilly H; Jardin F; Becker S
Clin Cancer Res; 2016 Aug; 22(15):3801-9. PubMed ID: 26936916
[TBL] [Abstract][Full Text] [Related]
36.
Girum KB; Rebaud L; Cottereau AS; Meignan M; Clerc J; Vercellino L; Casasnovas O; Morschhauser F; Thieblemont C; Buvat I
J Nucl Med; 2022 Dec; 63(12):1925-1932. PubMed ID: 35710733
[TBL] [Abstract][Full Text] [Related]
37. High total metabolic tumor volume at baseline predicts survival independent of response to therapy.
Vercellino L; Cottereau AS; Casasnovas O; Tilly H; Feugier P; Chartier L; Fruchart C; Roulin L; Oberic L; Pica GM; Ribrag V; Abraham J; Simon M; Gonzalez H; Bouabdallah R; Fitoussi O; Sebban C; López-Guillermo A; Sanhes L; Morschhauser F; Trotman J; Corront B; Choufi B; Snauwaert S; Godmer P; Briere J; Salles G; Gaulard P; Meignan M; Thieblemont C
Blood; 2020 Apr; 135(16):1396-1405. PubMed ID: 31978225
[TBL] [Abstract][Full Text] [Related]
38. Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network.
Blanc-Durand P; Jégou S; Kanoun S; Berriolo-Riedinger A; Bodet-Milin C; Kraeber-Bodéré F; Carlier T; Le Gouill S; Casasnovas RO; Meignan M; Itti E
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1362-1370. PubMed ID: 33097974
[TBL] [Abstract][Full Text] [Related]
39. Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient cohort.
Le Goff E; Blanc-Durand P; Roulin L; Lafont C; Loyaux R; MBoumbae DL; Benmaad I; Claudel A; Poullot E; Robe C; Gricourt G; Aissat A; Copie-Bergman C; Lemonnier F; Gaulard P; Itti E; Haioun C; Delfau-Larue MH
Br J Haematol; 2023 Jul; 202(1):54-64. PubMed ID: 37038217
[TBL] [Abstract][Full Text] [Related]
40. Baseline [
Yang Q; Luo Y; Zhang Y; Zhang W; Zhou D; Li F
Eur Radiol; 2022 Aug; 32(8):5568-5576. PubMed ID: 35316362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
